 Previous meta-analyses of randomized controlled trials have demonstrated that the long acting dihydropyridine calcium channel blocker amlodipine Norvasc, compared with other antihypertensive drugs, provides more protection against stroke. The benefit of amlodipine against stroke is approximately 10 greater than diureticsβ-blockers, and 20 greater than angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Of all the dihydropyridine calcium channel blockers, only amlodipine provides protection against myocardial infarction similar as angiotensin-converting enzyme inhibitors, diuretics and β-blockers, and more than angiotensin receptor blockers. The benefit of amlodipine in the prevention of stroke might be attributable to its 24-h blood pressure control. 